Cytomegalovirus infection following unrelated cord blood transplantation for adult patients: a single institute experience in Japan
Open Access
- 9 April 2003
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 121 (2) , 304-311
- https://doi.org/10.1046/j.1365-2141.2003.04264.x
Abstract
Summary. Cytomegalovirus (CMV) infection in 28 adult patients after cord blood transplantation (CBT) from unrelated donors was compared with that after bone marrow transplantation from HLA (human leucocyte antigen)‐matched related (R‐BMT) and unrelated (U‐BMT) donors. Positive CMV antigenaemia was seen in 19 (79%) of 24 CMV‐seropositive patients at a median of 42 d (range 29–85 d) after CBT, but in zero of four CMV‐seronegative patients. This did not differ significantly from values observed after R‐BMT and U‐BMT (66%, P = 0·22, and 60%, P = 0·15 respectively). Based on the antigenaemia results, 16 patients (67%) received pre‐emptive ganciclovir therapy from a median of 47 d (range 36–67 d) after CBT. This proportion was higher than that observed after R‐BMT (28%, P = 0·0048), but did not differ from that after U‐BMT (50%, P = 0·21). In addition, the probability of requiring more than two courses of ganciclovir therapy after CBT (21%) was higher than after R‐BMT and U‐BMT (0%, P = 0·015 and 0·039 respectively). One patient (5%) developed CMV disease after U‐BMT, whereas no patients developed CMV disease after CBT or R‐BMT. The CMV serostatus, use of a steroid and HLA disparity affected the probability of requiring ganciclovir therapy after CBT (P = 0·024, 0·032 and 0·017 respectively). These results suggest that recovery of CMV‐specific immunity after CBT is delayed when compared with BMT.Keywords
This publication has 19 references indexed in Scilit:
- Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplantsTransplantation, 2002
- Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantationBlood, 2002
- Hematopoietic Engraftment and Survival in Adult Recipients of Umbilical-Cord Blood from Unrelated DonorsNew England Journal of Medicine, 2001
- Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemiaBlood, 2001
- Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in JapanBone Marrow Transplantation, 2001
- Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipientsBlood, 2001
- A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapyBone Marrow Transplantation, 2000
- Outcomes among 562 Recipients of Placental-Blood Transplants from Unrelated DonorsNew England Journal of Medicine, 1998
- Outcome of Cord-Blood Transplantation from Related and Unrelated DonorsNew England Journal of Medicine, 1997
- Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes.Proceedings of the National Academy of Sciences, 1992